We identified 4 compounds, AZ960 [85], JAK8517, JAK18709 [86] and Ruxolitinib [87], that specifically target proteins in the JAK/STAT pathway and compared their drug sensitivity to PTPRM promoter methylation status in pancreatic cancer cell lines. Here, PTPRM is linked to familial pancreatic carcinoma.